Recent Press Releases

FDA issues final rule on changes to pregnancy and lactation labeling information for prescription drug and biological products

The U.S. Food and Drug Administration published a final rule today that sets standards for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of...

GSK statement on Established Products Portfolio

As announced at the Company's 2nd quarter results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio. The...

FDA approves Jakafi to treat patients with a chronic type of bone marrow disease

First FDA-approved drug for polycythemia vera The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone...

Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)

<0> Teva Pharmaceutical Industries Ltd.IR:United States, 215-591-8912, 215-591-3033orIsrael, 972 (3) 926-7656orPR:Israel, 972 (3) 926-7687orUnited States, 215-591-8974, 215-284-0213 </0>

Actress Adamari López And Amgen Launch Spanish-Language Chemotherapy: Myths Or Facts™ Website And Resources

Quimioterapia: Mitos y Realidades Aimed at Helping Spanish-Speaking Patients and Caregivers Take Control of Their Chemotherapy Journey


FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA


XTANDI™ (enzalutamide) Now Approved in Europe for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve

Enzalutamide significantly reduced the risk of radiographic progression or death by 81% compared with placebo Enzalutamide demonstrated a significant impact on overall survival compared to...

Genspera, Inc. Featured in Interview

SAN ANTONIO, Dec. 2, 2014 /PRNewswire/ -- GenSpera, Inc.

NICE draft guidance recommends eculizumab (Soliris) for treating very rare life-threatening blood disorder

NICE has today issued final draft guidance recommending eculizumab (Soliris, Alexion) for funding for treating atypical Haemolytic Uraemic Syndrome (aHUS). The draft recommendation depends on the...

EPIRUS Biopharmaceuticals introduces biosimilar Infimab in India

EPIRUS Biopharmaceuticals introduces biosimilar Infimab in India Infimab (BOW015) Launches one quarter ahead of schedule with commercialization partner Ranbaxy Laboratories Limited BOSTON - (Business...

Otsuka Pharmaceutical to Acquire Avanir Pharmaceuticals

Full-scale entry to neurologic diseases area widens core business presence in CNS TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. is pleased to announce an agreement with Avanir...

NICE set to recommend another leukaemia drug

NICE set to recommend another leukaemia drug NICE has issued further draft guidance for consultation that recommends obinutuzumab, marketed by Roche as Gazyvaro, for some people with untreated...

Eli Lilly and Company and AstraZeneca Initiate Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enroll more than 1,500 patients in 15 countries


Merck's HIV Education Campaign, I Design, Reveals Video and Poem Created by the HIV Community in Honor of World AIDS Day

Collective Voice of Community Embodies Culmination of "Getting Vocal" About Individualized Treatment around the Country


New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia

Filing completed less than two months after first European approval for IMBRUVICA®

SUNNYVALE, Calif., Dec.

Prof. Yitzhak Peterburg Elected Chairman of Teva's Board of Directors

Prof. Yitzhak Peterburg Elected Chairman of Teva's Board of Directors Dr. Sol J. Barer joins the Board JERUSALEM--(BUSINESS WIRE)--Nov. 26, 2014-- Teva Pharmaceutical Industries Ltd....